Update on Anticoagulation & Atrial Fibrillation
|
|
- Reginald Warner
- 7 years ago
- Views:
Transcription
1 Update on Anticoagulation & Atrial Fibrillation Review recent changes in guidelines for VTE prophylaxis Discuss risk benefit assessment for stroke prevention in atrial fibrillation Review recent updates to stroke prevention for atrial fibrillation Discuss new oral anticoagulants 1
2 Unit dose products and prefilled syringes preferred Use approved protocols to manage anticoagulation Implement a policy to address baseline risk and ongoing monitoring for anti coagulated patients Educate all providers and staff re: Monitoring, adherence, drug food interactions, ADRs Audit and improve safety practices AMDA, Joint Commission LTC Grade of recommendation Risk/Benefit Considerations 1A Strong recommendation, High quality evidence 1B Strong recommendation, Moderate quality evidence 1C Strong recommendation, Low/very low quality evidence 2A Weak recommendation, High quality evidence 2B Weak recommendation, Moderate quality evidence 2c Weak recommendation, Low/Very low quality evidence Benefits > burdens. Appropriate for most patients Benefits> burdens, but important study limitations OK for most patients Benefits>burdens, weaker studies. OK for most patients in many situations Benefits burdens. Strong studies. Patient circumstances and preferences important Benefits burdens. Study limitations. Patient circumstances and preferences important Uncertain benefit/burden balance. Weak studies. Other alternatives equally reasonable 2
3 Hospitalization increases VTE risk 8 fold Medical pts suffer 50 75% of hospital VTE events For 1,000 high risk patients, 34 fewer symptomatic VTE (CI 0 51) with prophylaxis No clear benefit with prophylaxis if low risk Patient preferences 1 bleeding event 1 symptomatic VTE averted 1 intracranial bleed 2.5 symptomatic VTE Kahn ST Chest 2012;141:e195S e226s Risk Factor Points Active CA 3 Prior VTE 3 Low mobility (Bed rest w BR privileges 3 days) 3 High Risk Known thrombophilic defect 3 4 points VTE rate 11% Trauma or surgery 1 month 2 Age 70 1 Heart or respiratory failure 1 Low Risk Acute MI or Acute stroke 1 VTE rate 0.3% Acute infection or rheumatologic disorder 1 BMI 30 Active hormonal treatment 1 1 Barbar S, J Thromb Haemost. 2010;8(11):
4 Risk Factor Points Risk Factor Points GFR GFR< Male 1 INR> Score < 7 0.4% Major 1.5% Any Age Age bleeding Current CA 2 Platelets < 50 K 4 Rheumatic dz 2 Bleeding < 3 mo before Central vein catheter 2 Active UGI ulcer Score % Major 7.9% Any bleeding ICU/CCU 2.5 Decousus H, Chest High risk medical patients Prophylaxis with LDUH, LMWH or fondaparinux (1B) Low risk medical patients No anticoagulant or mechanical prophylaxis (1B) Stop anticoagulant when mobile or discharged (1B) Kahn ST Chest 2012;141:e195S e226s 4
5 High risk patients who are bleeding or at high risk of bleeding No anticoagulant prophylaxis (1B) Substitute Graded Compression Stockings (GCS) (2C) or Intermittent Pneumatic Compression (IPC) devices (2C) When bleeding stops or risk is low Substitute anticoagulant prophylaxis for mechanical (2B) Kahn ST Chest 2012;141:e195S e226s Baseline VTE risk s/p Hip Fracture Surgery (HFS) Before % symptomatic VTE % % Shorter LOS Quicker mobilization and ambulation Surgical technique 5
6 Symptomatic VTE on LMWH is 0.8% LMWH reduces DVT risk 50 60%, Off prophylaxis symptomatic DVT rate 1.8% Symptomatic PE on LMWH 0.35% LMWH reduce PE risk 66% Off prophylaxis symptomatic PE rate 1% 35 day off prophylaxis symptomatic VTE rate 4.3% Post op Prophylaxis Day 0 14 Post op Prophylaxis Day Post op Prophylaxis Day o 35 No Prophylaxis VTE 2.8% PE 1% DVT 1.8% VTE 1.5% PE 0.5% DVT 1% VTE 4.3% PE 1.5% DVT 2.8% LMWH VTE 1.15% PE 0.35% DVT 0.8% VTE 0.65% PE 0.2% DVT 0.45% VTE 1.8% PE 0.55% DVT 1.25% Median off prophylaxis bleeding rate 1.5% Bleeding risk factor schema not well tested However, for major orthopedic surgery, the surgeryspecific risk far outweighs the contribution of the patient specific factors 6
7 Total Hip or Total Knee Arthroplasty Minimum days of LMWH, Fondaparinux (1B) Apixaban, Dabigatran, Rivaroxaban (1B) LDUH (1B) Adjusted dose VKA (1B) Aspirin (1B) Intermitted Pneumatic Cuff device (1C) Total Hip or Total Knee Arthroplasty LMWH preferred agent over Fondaparinux (2B) Apixaban, Dabigatran, Rivaroxaban (2B) LDUH (2B) Adjusted dose VKA (2C) Aspirin (2C) 7
8 Hip Fracture Surgery Minimum of days of; LMWH, Fondaparinux (1B) LDUH (1B) Adjusted dose VKA (1B) Aspirin (1B) IPCD (1C) 18 hours Hip Fracture Surgery LMWH preferred agent over; Fondaparinux, LDUH (2B) Adjusted dose VKA, aspirin (2C) (NO DATA on other oral anticoagulants) 35 days preferred over 14 days (2B) Major orthopedic surgery patients who decline or are uncooperative with injections or IPCD Recommended over other alternatives; Apixiban or dabigatran (1B) Rivaroxaban or adjusted dose VKA if API, DAB unavailable (1B) 8
9 Rivaroxaban approved for THA & TKA Not evaluated in HFS >10,000 pts in RCTs 10mg rivaroxaban/day vs enoxaparin 40mg/day LMWH wins out overall RIV reduces symptomatic DVT by 5/1,000 v ENOX RIV increases major bleeding by 9/1,000 v ENOX Dabigatran NOT approved for THA, TKA Not evaluated in HFS > 10,000 pts in RCTs DAB 200mg or 150 mg once daily vs ENOX 40 mg/day Overall, DAB similar to ENOX Quirky exceptions for the extremely curious Apixaban NOT approved for TKA, THA, HFS in US > 12,000 pts in RCT for TKA THA No HFS studies API 2.5 mg Q 12H v ENOX 40mg/day Overall, similar to LMWH Possibly 7 fewer DVT per 1,000 No difference in PE, mortality 9
10 ASA 160mg/day for 35 days (n=17,444) 43% got LMWH or LDUH!? 3 Fewer Non fatal PE per 1,000 over 35 days 15/1,000 vs 12/1,000 ( NS) 8 fewer symptomatic DVT per 1,000 over 35 days 20/1,000 vs 28/1,000 3 more major bleeding episodes 30/1,000 vs 27/1,000 2 fewer deaths 54/1,0o00 vs 52/1,000 (NS) Commonest sustained arrhythmia 1 Responsible for 15% of ischemic strokes Rhythm control strategies do not eliminate need for anticoagulation 2,3 Strokes occurring with therapeutic INR are less severe 4 Anticoagulation reduces A fib stroke risk by 66% 1 NNT 32 vs placebo 1.Singer DE Chest 2008:133:546S 592S 2. Wyse DG N Engl J Med 2002;347: VanGelder IC N Engl J Med 2002;347: Hylek EM N Engl J Med 1996;349:
11 Simple heuristics fail complex decisions Many thought traps confound the anticoagulation decision Algorithmic, evidence based approach provides data that can then be adapted to patient s values, goals, functional and cognitive status Are you betting with the patient s nickel? Miles, RW JAMDA 2007;8:349 54) Don t overestimate bleeding risk Calculate it, then reduce it Don t overestimate fall risk Get the facts, then reduce fall risk Don t underestimate anticoagulant benefits Don t overestimate benefits of antiplatelet agents Benefits seen with warfarin will be similar with new approved oral anticoagulants Adverse effects seen with warfarin may be the same or less likely with new approved oral anticoagulants Similar assumptions and decision processes apply to warfarin and new approved oral anticoagulants 11
12 Patients rate non fatal stroke worse than 3 major bleeding episodes ACCP endorses only treatments that prevent 3 or more strokes for every major bleeding event For all cause mortality, no difference exists between current treatment options All options are better than no treatment You JJ. Chest 2012;141:e Median annual major bleeding risk 1.3% 0.8% above Baseline Risk of 0.5%/yr (not ALL major bleeding is due to anticoagulation) Fatality rates Extracranial bleeding 15% Hemorrhagic stroke 50% Ischemic stroke 25% Anticoagulant efficacy 66% fewer strokes 25% fewer deaths You JJ. Chest 2012;141:e
13 Score CVA per 10,000/yr point each for CHF or LVEF< 50% Hypertension Age Diabetes points for 5 1,250 Stroke or TIA 6 1,820 Gage, BF JAMA 2001;285: CHADS2 ACCP 2012 Stroke Risk Gage % 1.9% 1 2.2% 2.8% 2 4.5% 4.0% % % You JJ. Chest 2012;141:e ACCP bases stroke risk on updated CHADS 2 Updated risks based on data from recent studies Predictive value of updated estimates untested CHADS has poor predictive value, but is best CHADS does not account for continuous increase in stroke risk with increasing age You JJ. Chest 2012;141:e
14 Oral anticoagulation (OAC) preferred to no therapy (1A) OAC preferred to aspirin (1B) OAC preferred to aspirin plus clopidogrel (1B) Aspirin plus clopidogrel preferred to aspirin alone, if unable or unwilling to take OAC (1B) You JJ. Chest 2012;141:e Educate patients that antiplatelet therapy is inferior to oral anticoagulant treatment for stroke prevention. Dabigatran 150 mg twice daily preferred to warfarin (2B) 2B Weak recommendation Benefits burdens. Moderate quality evidence Study limitations. Patient circumstances and preferences important You JJ. Chest 2012;141:e c Weak recommendation Uncertain benefit/burden balance Other alternatives equally reasonable Weak studies. Low/Very low quality evidence 14
15 Stable coronary artery disease (CAD) Warfarin (VKA) alone preferred to VKA plus aspirin (2C) S/P acute coronary syndrome (ACS), no PCI or stent VKA plus single antiplatelet agent for 12 months (2C) After 12 mo, VKA alone preferred to VKA +ASA (2C) You JJ. Chest 2012;141:e PCI with bare metal stent (BMS) VKA + ASA+ clopidogrel for 1 mo (2C) 12 mo triple therapy if high risk of late stent thrombosis VKA + single antiplatelet agent 2 12 mo (2C) After 12 mo, VKA alone preferred to VKA + ASA (2C) You JJ. Chest 2012;141:e PCI with paclitaxel DES VKA + ASA + Clopidogrel for 1 6 mo (2C) 12 mo triple therapy if high risk of late stent thrombosis VKA + single antiplatelet agent rest of year after triple tx (2C) After 12 mo, VKA alone preferred to VKA + ASA (2C) You JJ. Chest 2012;141:e
16 PCI with sirolimus, zotarolimus, everolimus DES VKA + ASA + Clopidogrel for 3 6 mo (2C) 12 mo triple therapy if high risk of late stent thrombosis VKA + single antiplatelet agent rest of year after triple tx (2C) After 12 mo, VKA alone preferred to VKA + ASA (2C) You JJ. Chest 2012;141:e SDH rate = per elderly pt/year 4 per 10,000 pt yrs 33% >65 fall at least once/year 10% of falls cause major injury 70% of elderly SDH have head trauma Half of these associated with a fall Man-Son- Hing Arch Intern Med 1999:159;
17 70% of elderly SDH have head trauma 50% of SDH due to trauma are due to falls RR of SDH among those who fall = X.0004 = SDH/pt year of fallers Net increase of 1 2 SDH per ten thousand patients among those who fall Man-Son- Hing Arch Intern Med 1999:159; Persons taking coumadin must fall approximately 295 times in 1 year before coumadin is no longer the optimal therapy Fracture more likely than SDH Man-Son- Hing Arch Intern Med 1999:159; Retrospective chart review hospital falls SDH, major bleeding 2664 falls in 1861 patients 50% on antithrombotic therapy 1.4% falls caused fracture 10% had major hemorrhagic injury warfarin 6%, no therapy 11% p0.01 OR: 1.6 female, 1.4 ASA, 2.2 clopidogrel No increased risk with warfarin, INR level 1 fatal SDH (ASA + warfarin with INR 4.3) Bond AJ Thrombosis Journal 2005;3:1 17
18 Treat AF with warfarin to INR 2 3 Falling raises SDH risk 1 2/10,000 If stroke rate 2%, fall rate 100%, warfarin still better than no treatment Bleeding and fall risk factors identifiable May be modifiable 8932 pts,15 randomized groups,12 studies A fib independently increases stroke risk 5 fold Overall stroke risk increases with age, so the influence of AF increased with age. OACS >AP > placebo to decrease the risk of ischemic stroke and CV events. van Walraven, C. et al. Stroke 2009;40:
19 Hazard Ratios below 1 indicate that treatment decreased the risk When the confidence interval of the hazard Ratio excludes 1, the result is statistically significant (p <.05) van Walraven, C. et al. Stroke 2009;40: OAC Effectiveness Persists van Walraven, C. et al. Stroke 2009;40: Antiplatelet Effectiveness Wanes van Walraven, C. et al. Stroke 2009;40:
20 OAC benefit persists with age AP benefit decreases with age Hemorrhagic risk similar OAC and AP Real world patients likely sicker than RCT patients Bleeding risk may be higher, INR control worse van Walraven, C. et al. Stroke 2009;40: Expected net clinical benefit...is highest among patients with the highest untreated risk for stroke, which includes the oldest age category. risk assessment that incorporates both risk of thromboembolism and risk for intracranial hemorrhage provides a more quantitatively informed basis for the decision. How much better and safer? 20
21 Dabigatran ( RE LY) Direct thrombin inhibitor Rivaroxaban ( Rocket AF) Factor Xa Inhibitor Apixaban (ARISTOTLE) Factor Xa Inhibitor Comparisons difficult due to different study populations Not very many patients like our LTC patients Age, GFR In general, equivalent or better than warfarin Less intracerebral hemorrhage Same or less hemorrhage Same or less overall negative outcomes RE LY Dabigatran ROCKET AF Rivaroxaban ARISTOTLE Apixaban CHADS2 DAB 150mg Warfarin RIV Warfarin APIX Warfarin Mean % 31% % 34% 2 35% 37% 13% 13% 36% 36% % 32% 87% 87% 30% 30% 21
22 RE LY Dabigatran ROCKET AF Rivaroxaban ARISTOTLE Apixaban DAB 150mg Warfarin RIV Warfarin APIX Warfarin Age 72 (63 80) 72 (62 80) 73 (65 78) 73 (65 78) 70 (63 76) 70 (63 76) CVA,TIA,V TE 20% 20% 55% 55% 19% 19% GFR Median 67 (52 88) Median 67 (52 88) 15% 15% GFR < 30 Exclude Exclude 1.5% 1.55 RE LY Dabigatran ROCKET AF Rivaroxaban ARISTOTLE Apixaban DAB 150mg Warfarin RIV Warfarin APIX Warfarin CVA/VTE 1.11%/yr 1.6%/yr 2.1%/yr 2.4%/yr 1.27%/yr 1.6%/yr Ischemic 0.92%/yr 1.20%/yr 0.97%/yr 1..51%/yr Hemorrhagic 0.1%/yr 0.38%/yr 0.5%/yr 0.7%/yr 0.24%/yr 0.47%/yr CVA,VTE, MI, death 4.85%/yr 5.49%/yr RE LY Dabigatran ROCKET AF Rivaroxaban ARISTOTLE Apixaban DAB 150mg Warfarin RIV Warfarin APIX Warfarin Major bleed 1.45%/yr 1.8%/yr 3.6%/yr 3.4%/yr 4.07%/yr 6.01%/yr Minor bleed 14.8%/yr 16.4%/yr 11.8%/yr 16.2%/yr Bleed, MI, Vasc event, death 6.91%/yr 7.09%/yr 3.17%/yr 4.11%/yr 22
23 INR below 2.0 results in a higher risk of stroke Hylek EM, et al. NEJM 1996;335: Hylek EM, Singer DE, Ann Int Med 1994;120:
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
More informationKevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More informationAtrial Fibrillation: Stroke and Thromboprophylaxis. Derek Waller
Atrial Fibrillation: Stroke and Thromboprophylaxis Derek Waller Atrial Fibrillation in the Elderly: Risk of Stroke Framingham study AGE 50-59 60-69 70-79 80-89 Prevalence of AF % Attributable Risk of AF
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationNone. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015
Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationNew Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
More informationAnticoagulation For Atrial Fibrillation
Anticoagulation For Atrial Fibrillation New Agents In A New Era Arjun V Gururaj, MD Arrhythmia and Electrophysiology Nevada Heart and Vascular Center Disclosures Biotronik Speaker Clinical investigator
More information3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
More informationRR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) 3.75
ALL-CAUSE MORTALITY RR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) Rate per year (%) 5.0 4.0 3.0 2.0 1.0 0 3.64 D150 mg BID 3.75 D110 mg BID RR 0.91 (95% CI: 0.80 1.03) P=0.13 (superiority) 4.13 Warfarin
More informationTime of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More informationAnticoagulation Therapy Update
Anticoagulation Therapy Update JUDY R. WALLING, FNP-BC ARRHYTHMIA MANAGEMENT MUSC CARDIOLOGY Outline Who do we anticoagulate? Review classes of Anticoagulants Review examples of Anticoagulants Review CHADS2
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationThe 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012
The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
More informationFailure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ. Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν
ΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν The AF epidemic Mayo Clinic data (assuming a continued increase in the AF incidence) Mayo
More informationNew Anticoagulants and GI bleeding
New Anticoagulants and GI bleeding DR DANNY MYERS MD FRCP(C) CLINICAL ASSISTANT PROFESSOR OF MEDICINE, UBC Conflicts of Interest None I am unbiased in the use of NOAC s vs Warfarin based on risk benefit
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationNew Oral AntiCoagulants (NOAC) in 2015
New Oral AntiCoagulants (NOAC) in 2015 William R. Hiatt, MD Professor of Medicine and Cardiology University of Colorado School of Medicine President CPC Clinical Research Disclosures Received research
More information9/5/14. Objectives. Atrial Fibrillation (AF)
Novel Anticoagulation for Prevention of Stroke in Patients with Atrial Fibrillation Objectives 1. Review current evidence on use of warfarin in individuals with atrial fibrillation 2. Compare the three
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More information3/3/2015. Patrick Cobb, MD, FACP March 2015
Patrick Cobb, MD, FACP March 2015 I, Patrick Cobb, MD, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict
More informationAnalyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
More informationCardiovascular Disease
Cardiovascular Disease 1 Cardiovascular Disease 1. More target specific oral anticoagulants (TSOAC) 2. Vorapaxar (Zonivity) 3. Continued noise about a polypill 4. WATCHMAN 3 1 2 3 4 Left Atrial Appendage
More informationThe Anti coagulated Patient: The Cardiologist s View. February 28, 2015
The Anti coagulated Patient: The Cardiologist s View February 28, 2015 Conflicts Dr. McMurtry has no conflicts to disclose. CanMeds Medical Expert (as Medical Experts, physicians integrate all of the CanMEDS
More informationTraditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
More informationAtrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE
Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE Clinical practice guidelines serve as an educational reference, and do not supersede the clinical judgment of the treating physician with
More informationBreadth of indications matters One drug for multiple indications
Breadth of indications matters One drug for multiple indications Sylvia Haas, MD, PhD Formerly of the Technical University of Munich Munich, Germany Disclosures: Sylvia Haas 1 Novel oral anticoagulants:
More informationAnticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014
Anticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014 Atrial Fibrillation 2 Atrial Fibrillation The most common arrhythmia encountered
More informationObjectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants
Objectives New and Emerging Anticoagulants Adraine Lyles, PharmD, BCPS Clinical Pharmacy Specialist VCU Medical Center Describe the pharmacology of the novel oral anticoagulants Discuss the clinical evidence
More informationThrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
More informationNew Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis Mark Crowther 1 Disclosures Advisory Boards in last 24 months Pfizer, Alexion, Bayer, CSL Behring,
More informationAdvanced Issues in Peri-Operative VTE Prevention
Advanced Issues in Peri-Operative VTE Prevention Michael-Anthony (M-A) Williams, M.D. Consultant Physician Centura Medical Consultants September 27th, 2012 Main Topics 1. The perils of the early mover-
More informationHow To Treat Aneuricaagulation
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
More informationGoals 6/6/2014. Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs. Ashkan Babaie, MD
Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs Ashkan Babaie, MD Arrhythmia Service Providence Heart Clinic June 8 th, 2014 Goals Discuss the data behind approval of NOACs
More informationTherapeutic Class Overview Oral Anticoagulants
Therapeutic Class Overview Oral Anticoagulants Therapeutic Class Overview/Summary: The oral anticoagulants, dabigatran etexilate mesylate (Pradaxa ), rivaroxaban (Xarelto ), and warfarin (Coumadin, Jantoven
More informationNew Anticoagulants: What to Use What to Avoid
New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA
More informationABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
More information6/19/2012. Update on Venous Thromboembolism Prophylaxis. Disclosure. Learning Objectives. No conflicts of interest to declare
Update on Venous Thromboembolism Prophylaxis Disclosure No conflicts of interest to declare Learning Objectives After completion of this presentation, participants should be able to: Define venous thromboembolism,
More informationAnticoagulation for NVAF: NAOs or AVKs? Giancarlo Agnelli
Anticoagulation for NVAF: NAOs or AVKs? Giancarlo Agnelli Medicina Interna & Cardiovascolare - Stroke Unit Scuola di Specializzazione in Medicina di Emergenza - Urgenza Università di Perugia My talk today
More informationLimitations of VKA Therapy
Fibrillazione Atriale Non Valvolare Ischemia o Emorragia le Due Utopie Rivali nella Scelta dei NAO Gianluca Botto, MD, FESC, UO Elettrofisiologia, Dip Medicina Limitations of VKA Therapy Unpredictable
More informationReview of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain
Review of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain Dr Alexander (Ander) Cohen Guy s and St Thomas Hospitals, King s College London, UK Pavia Spring Meeting 13 June 2014 Overview
More informationNew in Atrial Fibrillation
New in Atrial Fibrillation September 2011 Stroke prevention more options Rhythm Control -drugs - alternatives to drugs; ablation Rate Control - pace + ablate A-FIB Dell Stroke Risk AFib Two Principles
More informationHow To Understand The History Of Analgesic Drugs
New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century David Stewart, PharmD, BCPS Associate Professor of Pharmacy Practice East Tennessee State University
More informationDevang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
More informationANTICOAGULATION USE FOR THE PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISEASE
ANTICOAGULATION USE FOR THE PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISEASE Jamie N. Nadler, M.D. Assistant Professor of Medicine State University of New York at Buffalo Department of medicine Division
More informationPublished 2011 by the American Academy of Orthopaedic Surgeons 6300 North River Road Rosemont, IL 60018. AAOS Clinical Practice Guidelines Unit
Volume 4. AAOS Clinical Guideline on Preventing Venous Thromboembolic Disease in Patients Undergoing Elective Hip and Knee Arthroplasty Comparison with Other Guidelines Disclaimer This clinical guideline
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More informationDabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM This report was commissioned by the NIHR HTA Programme as project number 12/78
More informationThe speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
More informationCurrent and new oral Anti-coagulation. Lancashire and Cumbria Network 2 February 2012
Current and new oral Anti-coagulation Lancashire and Cumbria Network 2 February 2012 Question Warfarin is an abbreviation What does the W stand for? What is this plant and what is the connection with warfarin?
More information2.5mg SC daily. INR target 2-3 30 mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.
Anticoagulation dosing at UCDMC (SC=subcutaneously; CI=continuous infusion) Indication Agent Dose Comments Prophylaxis Any or No bleeding risk factors see adult heparin (VTE prophylaxis) IV infusion order
More informationUpdate on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD
Update on Antiplatelets and anticoagulants Timir Paul, MD, PhD Antiplatelets Indications Doses Long term use (beyond 12 months) ASA and combination use of NSAIDS ASA resistance Plavix resistance Plavix
More informationCardiology Update 2014
Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The
More informationAtrial Fibrillation: A Different Perspective. Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital
Atrial Fibrillation: A Different Perspective Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital Faculty/Presenter Disclosure Faculty: Dr. Michael Heffernan Relationships with commercial
More informationTraveller s Thrombosis. Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven
Traveller s Thrombosis Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven Case 1: To thromboprophylaxe or not Women, aged 49, BMI 29, Combined Oral Contraceptives. Family history of provoked
More informationPrevention of stroke in patients with atrial fibrillation
www.sign.ac.uk Prevention of stroke in patients with atrial fibrillation A guide for primary care January 2014 Evidence Contents 1 Introduction... 1 2 Detection...2 3 Risk stratification... 3 4 Treatment
More informationProgram Objectives. Why Use Anticoagulants? 6/5/2014
Larry Reis RPh CGP FASCP Prepared June 2014 for NADONA REIS RXCARE CONSULTING Reisrxcare@comcast.net 1 Program Objectives Discuss complications of current anticoagulant Rx Identify risks of using anticoagulants
More informationBios 6648: Design & conduct of clinical research
Bios 6648: Design & conduct of clinical research Section 1 - Specifying the study setting and objectives 1. Specifying the study setting and objectives 1.0 Background Where will we end up?: (a) The treatment
More informationRivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012
Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Agenda Ideal anticoagulant. Drawbacks of warfarin. Rivaroxaban in clinical trails. Present
More informationManagement of Antithrombotics with Procedures. Jordan Weinstein, MD
Management of Antithrombotics with Procedures Jordan Weinstein, MD Presenter Disclosure Information Cardiology Update 2013 I have no relevant financial interest and/or arrangement with industry. Novel
More informationCommittee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
More informationAnticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h
Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h See EMR adult VTE prophylaxis CI order set Enoxaparin See service specific dosing Assess
More informationGetting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot
Getting smart about dyspnea and life saving drug therapy in ACS patients Kobi George Kaplan Medical Center Rehovot 78 year old female Case description Presented with resting chest pain and dyspnea Co morbidities:
More informationOptimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015
Optimizing Anticoagulation Selection for Your Patient C. Andrew Brian MD, FACC NCVH 2015 Who Needs to Be Anticoagulated and What is the Patient s Risk? 1. Atrial Fibrillation ( nonvalvular ) 2. What regimen
More informationFinancial Disclosures
Financial Disclosures Consulting: AstraZeneca, Bayer, Boehringer Ingleheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Glaxo Smith Kline, Johnson & Johnson, Merck, Novartis, Ortho/McNeill, Pfizer,
More informationWOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast
WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION Van Crisco, MD, FACC, FSCAI First Coast Conflicts of Interest I have been a paid consultant and speaker for AstraZeneca, makers of
More informationAnticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk
Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart
More informationNew Anticoagulation Agents
New Anticoagulation Agents Use of New and Older Therapeutic Agents in the Treatment Regimen Michelle Geddes Case 1 40 year old woman with idiopathic proximal DVT. Previous heparin allergy (wheals, hives)
More informationAre there sufficient indications for switching to new anticoagulant agents
Are there sufficient indications for switching to new anticoagulant agents Meyer Michel Samama et Gregoris Gerotziafas Groupe Hémostase-Thrombose Hôtel-Dieu, Hôpital Tenon, Paris & Biomnis Ivry/seine,
More information1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
More informationApixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
More informationThe Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More informationDirect Oral Anticoagulants (DOACs) Who Gets What?
Direct Oral Anticoagulants (DOACs) Who Gets What? Kathryn Hassell, MD Professor of Medicine, Division of Hematology University of Colorado Denver Disclosures No financial or commercial conflicts of interest
More informationxaban) Policy covered: Coverage of following criteria: the following those who meet the or Hip Xarelto is For those impacted by this policy.
Xarelto (rivarox xaban) Policy Number: 5.01.575 Origination: 06/2014 Last Review: 07/2015 Next Review: 07/2016 Policy BCBSKC will provide coverage for Xarelto when it is determined to be medically necessary
More informationTHE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
More informationAnticoagulation before and after cardioversion; which and for how long
Anticoagulation before and after cardioversion; which and for how long Sameh Samir, MD Cardiovascular medicine dept. Tanta faculty of medicine Atrial fibrillation goals of management Identify and treat
More informationXarelto (Rivaroxaban): Effective in a broad spectrum. Joep Hufman, MD Medical Scientific Liason
Xarelto (Rivaroxaban): Effective in a broad spectrum Joep Hufman, MD Medical Scientific Liason Xarelto : Effective in a broad spectrum Introduction Therapeutic areas SPAF VTE Prevention VTE treatment Practical
More informationEliquis. Policy. covered: Eliquis is. indicated to. reduce the. therapy. Eliquis is. superior to. of 32 to. Eliquis is AMPLIFY. nonfatal. physicians.
Eliquis (apixaban) Policy Number: 5.01.573 Origination: 06/2014 Last Review: 07/2015 Next Review: 07/2016 Policy BCBSKC will provide coverage for Eliquis when it is determined to be medically necessary
More informationManagement of atrial fibrillation. Satchana Pumprueg, MD Sirin Apiyasawat, MD Thoranis Chantrarat, MD
Management of atrial fibrillation Satchana Pumprueg, MD Sirin Apiyasawat, MD Thoranis Chantrarat, MD Antithrombotic therapy in atrial fibrillation Satchana Pumprueg, MD AF has serious consequences Independent
More information5/21/2012. Perioperative Use Issues. On admission: During hospitalization:
Dabigatran and Rivaroxaban: Challenges in the Perioperative Setting Claudia Swenson, Pharm.D., CDE, BC-ADM, FASHP Central Washington Hospital Wenatchee, WA claudia.swenson@cwhs.com Dabigatran and Rivaroxaban:
More informationDirect oral anticoagulants in daily care: what do we know today and what are the remaining issues?
De afbeelding kan niet worden weergegeven. Mogelijk is er onvoldoende geheugen beschikbaar om de afbeelding te openen of is de afbeelding beschadigd. Start de computer opnieuw op en open het bestand opnieuw.
More informationWhat Does Pregnancy Have to Do With Blood Clots in a Woman s Legs?
Patient s Guide to Prevention of Blood Clots During Pregnancy: Use of Blood-Thinning A Patient s Guide to Prevention of Blood Clots During Pregnancy: Use of Blood-Thinning Drugs to Prevent Abnormal Blood
More informationFOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE
www.bpac.org.nz keyword: warfarinaspirin FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE Key Concepts In atrial fibrillation (AF) warfarin is more effective than aspirin for stroke prevention.
More informationInvestor News. Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint. Not intended for U.S.
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint
More informationNICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals NICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation 1
More informationDuration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
More informationPeter Thomson. Clinical Resource Pharmacist, WRHA Medicine Program Clinical Asst Professor, Faculty of Pharmacy, University of Manitoba
Rivaroxaban Expanding Beyond Orthopedics Peter Thomson Clinical Resource Pharmacist, WRHA Medicine Program Clinical Asst Professor, Faculty of Pharmacy, University of Manitoba Objectives Compare key pharmacologic
More informationAnticoagulation in Atrial Fibrillation
Anticoagulation in Atrial Fibrillation Parag P. Patel, MD FACC Disclosures Eliquis Speakers Bureau 1 Clinical Scenario Ms. L is a 76F admitted to the stroke service with a dense right sided hemiparesis
More informationManagement for Deep Vein Thrombosis and New Agents
Management for Deep Vein Thrombosis and New Agents Mark Malesker, Pharm.D., FCCP, FCCP, FASHP, BCPS Professor of Pharmacy Practice and Medicine Creighton University 5 th Annual Creighton Cardiovascular
More informationWhat s New in Stroke?
5 th McMaster University Review Course in INTERNAL MEDICINE What s New in Stroke? Robert Hart, M.D. HHS / McMaster Stroke Program Department of Medicine (Neurology) McMaster University Hamilton, Ontario
More informationCurrent Controversies in Management of Anticoagulation for Atrial Fibrillation
Current Controversies in Management of Anticoagulation for Atrial Fibrillation Cheri Silverstein Fadlon, MD MSCR Assistant Professor of Internal Medicine, COMP Cardiologist, Western Diabetes Institute
More informationNew Oral Anticoagulants: Topic Brief
New Oral Anticoagulants: Topic Brief June 9, 2015 High-Level Research Question In patients with nonvalvular atrial fibrillation (AF) or venous thromboembolic disease, or who have undergone surgery for
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More information